




RealRate

PHARMACEUTICAL 2015

ELI Lilly Co
Rank 160 of 274

Lilly



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 9.4% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	12,179,800
Cost of Goods Sold	0
Intangible Assets	4,642,300
Liabilities, Current	11,207,500
Liabilities, Non-Current	10,582,600
Other Assets	12,392,200
Other Compr. Net Income	-1,989,100
Other Expenses	5,870,700
Other Liabilities	0
Other Net Income	0
Other Revenues	19,615,600
Property and Equipment	7,963,900
Research and Development	4,733,600
Selling, General and Administrative Expense	6,620,800

Output Variable	Value in 1000 USD
Assets	37,178,200
Liabilities	21,790,100
Expenses	17,225,100
Revenues	19,615,600
Stockholders Equity	15,388,100
Net Income	2,390,500
Comprehensive Net Income	1,395,950
BaseVar	48,899,050
ECR before Limited Liability	119%
Economic Capital Ratio	245%